2026– date –
-
FDA Details Regenerative Medicine Advanced Therapy (RMAT) Designation Framework, Offering Fast Track and Breakthrough Therapy Benefits
Global MedTech Expert USA Overview Global MedTech Expert details the FDA's regulatory framework for 351/361 HCT/P classification and Regenerative Medicine Advanced Therapy (RMAT) designation. RMAT offers significant benefits, including F... -
BioPharma Dive Reports on Cell and Gene Therapy Manufacturing Frontlines: Viral Vector Supply Shortages and CDMO Market Soaring to $9.08 Billion by 2031
BioPharma Dive USA Overview BioPharma Dive analyzes key challenges and commercial opportunities in cell and gene therapy manufacturing, pinpointing viral vector production as the most severe supply constraint. Lonza is significantly expa... -
Liv Hospital Pioneers iPSC-Driven 3D Bioprinting and Organoid Development, Reshaping Organ Transplantation
Liv Hospital Turkey Overview Liv Hospital is at the forefront of research highlighting the pivotal role of induced pluripotent stem cell (iPSC) lines in advancing 3D bioprinting and organoid development. These initiatives aim to engineer... -
Unlocking Exosome Therapies for Corneal Disorders: Overcoming the Clinical Translation Challenge
Annals of Translational Medicine China Overview A recent review in *Annals of Translational Medicine* underscores the significant hurdles facing exosome-based therapies for corneal disorders, primarily in achieving manufacturing standard... -
Gene Editing Startup Race Intensifies: CRISPR Therapeutics Leads in Commercialization, Intellia Advances In Vivo Phase 3, Beam Demonstrates Base Editing Versatility Across Human Therapies
New Market Pitch USA Overview A New Market Pitch analysis reveals CRISPR Therapeutics leads in commercialization with approved therapies, while Intellia Therapeutics shows significant progress in Phase 3 in vivo gene editing trials. Beam... -
BioInformant Details 2026 iPSC-Derived Cell Therapeutics Pipeline: Key Players Accelerate Clinical Development for Parkinson’s, Heart Failure, Cancer, and More
BioInformant USA Overview BioInformant's comprehensive report outlines the 2026 pipeline for iPSC-derived cell therapeutics, highlighting progress from key companies like Fate Therapeutics, BlueRock Therapeutics, FUJIFILM Cellular Dynami... -
University of Queensland Develops Scalable Engineered Extracellular Vesicles for Enhanced Targeted Delivery to Ovarian Cancer
Medical Xpress (University of Queensland) Australia Overview Researchers at the University of Queensland have developed scalable engineered extracellular vesicles (EVs) capable of targeted molecular cargo delivery to ovarian tumors. This... -
Converging 3D Bioprinting with Organoid Technology Accelerates Precision Medicine and Tissue Engineering
Oxford Academic (Regenerative Biomaterials) UK Overview A recent review highlights the transformative potential of integrating 3D bioprinting with organoid technology, opening new avenues for personalized medicine and advanced tissue eng... -
Precision Gene Editing with Adenine Base Editors Restores Muscle Function in Childhood FSHD Model, Advancing Gene Therapy
bioRxiv Australia Overview This study presents a novel therapeutic strategy for childhood-onset Facioscapulohumeral Muscular Dystrophy (FSHD), an intractable genetic disorder. Researchers leveraged an iPSC-derived skeletal muscle model t... -
Century Therapeutics Pivots iPSC Platform to Type 1 Diabetes Beta Cell Therapy, Targeting 2025 IND with Off-the-Shelf Approach
Century Therapeutics USA Overview Century Therapeutics has announced a strategic realignment of its induced pluripotent stem cell (iPSC) platform, now exclusively dedicated to developing beta islet cell therapy for Type 1 Diabetes. The c...
